NephroGenex could sell 2,008,032 shares in its $15 million public sale

Bookrunners Canaccord Genuity and JMP Securities will assist with sale

By Devika Patel

Knoxville, Tenn., June 25 – NephroGenex, Inc. plans to raise $15 million in its public sale of common stock with a 45-day greenshoe, according to an S-1/A and an FWP filed Thursday with the Securities and Exchange Commission. The company has registered up to $17.25 million of stock for the sale, which was announced April 20.

The company will sell 2,008,032 shares, assuming an offering price of $7.47 per share, which was the closing price of the stock (Nasdaq: NRX) on June 24.

Aegis Capital Corp. is the bookrunner.

Proceeds will be used for clinical development, working capital and general corporate purposes.

The Research Triangle Park, N.C., pharmaceutical company develops therapeutics to treat kidney disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.